TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06084845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chest Radiography
Description: Undergo chest x-ray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest Radiography
Description: Undergo chest x-ray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT and/or PET-CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and/or PET-CT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Image Guided Radiation Therapy
Description: Undergo IGRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image Guided Radiation Therapy
Description: Undergo IGRT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET-CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET-CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xevinapant
Description: Given PO
Study: NCT04792801

Intervention type: RADIATION
Intervention: PET TDM FDG-Choline
Description: Performing an FDG TDM PET and a Choline TDM PET at two different times
Study: NCT04795193

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimal invasive coronary surgery
Description: Off-pump multi-vessel coronary artery bypass grafting via left thoracotomy under minimally invasive conditions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Off-pump coronary artery bypass surgery
Description: Off-pump multi-vessel coronary artery bypass grafting with conventional thoracotomy.
Study: NCT06062121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motor-cable-driven Rehabilitation Robotic System
Description: Subjects will wear the motor-cable-driven system and receive 30 minutes (including preparation time) wrist and forearm robot-assisting exercise
Study: NCT05887258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid free anesthesia
Description: It administers a combination of drugs to replace the opioid derivatives. Among them, we will use lidocaine, ketamine, dexmetomidine, and magnesium sulfate in continuous infusion adjusted to the patient's weight during surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid based Anesthesia
Description: administer anesthesia based on opioids such as fentanyl and/or morphine to guarantee analgesia during the surgical intervention.
Study: NCT05394259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piflufolastat F18
Description: Given by vein (IV)
Study: NCT04767997

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic formulation
Description: Participants will be asked to take one capsule daily, containing 3 billion CFU of the probiotics.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be asked to take a placebo capsule daily.
Study: NCT04406584

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection into olfactory cleft
Description: Already stated above.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Injection into olfactory cleft
Description: Already stated above.
Study: NCT05838365

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zirconia implant
Description: (Test group; within 7 days of implant placement) versus delayed (Control group; 8 weeks after implant placement)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zirconia implant
Description: (Test group; within 7 days of implant placement) versus delayed (Control group; 8 weeks after implant placement)
Study: NCT04967885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Implementation Intentions Intervention (EMI-II)
Description: To reduce smoking, this text messaging intervention will use a self-regulatory strategy, Implementation Intentions (II) to deliver appropriate alternative responses to cigarette smoking. Participants will create personalized II messages before starting the two-week intervention period. Then during the intervention period, after receiving Ecological Momentary Assessments (EMAs), participants will be micro-randomized to receive the EMI-II. During the EMA + EMI-II period, participants will complete five daily EMAs. After approximately 40% of these EMAs, participants will also receive the personalized EMI-II by text messaging.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ecological Momentary Implementation Intentions Intervention (EMI-II)
Description: To reduce smoking, this text messaging intervention will use a self-regulatory strategy, Implementation Intentions (II) to deliver appropriate alternative responses to cigarette smoking. Participants will create personalized II messages before starting the two-week intervention period. Then during the intervention period, after receiving Ecological Momentary Assessments (EMAs), participants will be micro-randomized to receive the EMI-II. During the EMA + EMI-II period, participants will complete five daily EMAs. After approximately 40% of these EMAs, participants will also receive the personalized EMI-II by text messaging.
Study: NCT04923113

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Histology，13C urea breath test，Stool antigen test，Serological antibody test for H.pylori and Serologic test with a current infection marker of H.pylori
Description: The above 5 detection methods will be performed in patients who meet the inclusion criteria to detect H. pylori infection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole，Minocycline，Amoxicillin and Colloidal bismuth pectin
Description: Helicobacter pylori positive patients will be treated with rabeprazole10mg,minocycline 100mg,amoxicillin1000mg,and colloidal bismuth pectin 200mg,all twice daily for 10 days
Study: NCT05438654

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Point of care ultrasound
Description: Abdominal PoCUS use according to the following protocol:~PoCUS assessment of the right lung base PoCUS assessment of Morrison's pouch PoCUS assessment of gallbladder PoCUS assessment of right kidney (comparison to left kidney acceptable) PoCUS assessment of small bowel
Study: NCT06524999

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Description: This intervention consists of two parts. The first part gives short information about the content and how exercises should be done. It consists of information about deep relaxation. In the second part, there are relaxation exercises accompanied. Both the briefing and the intervention lasted 30 minutes for each patient.
Study: NCT04509895

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral extensile approach in calcaneal fractures fixation
Description: The standard extended lateral approach with L-shaped incision was made in this group, which originated vertically from 5 cm over lateral malleolus or the midpoint between the fibula and Achilles tendon and ended on the base of the fifth metatarsal . The incision is made directly to the bone at the corner to create a full-thickness flap. Attention must be paid to protect the sural nerve and peroneal tendons as well.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive sinus tarsi approach in calcaneal fractures fixation
Description: An incision is made from the tip of the lateral malleolus toward the base of the fourth metatarsal bone. The incision lies in a plane between the superficial peroneal nerve and the sural nerve. Care is taken to bluntly dissect after the skin incision to protect the sural nerve or branches of the superficial peroneal nerve. By mobilizing the sinus tarsi fat pad dorsally, the incision was deepened. The extensor digitorum brevis muscle is sharply elevated off of the anterior process with the lateral root of the inferior extensor retinaculum and reflected dorsally and distally. The peroneus brevis and peroneus longus tendons are split, allowing exposure to the sinus tarsi and visualization of the posterior facet of the subtalar joint.
Study: NCT05865743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDD
Description: The intervention group receives SDD treatment additional to standard care, comprising two distinct liquids for oral administration: first the 5 ml amphotericin B suspension (100 mg/ml) and subsequently the 5 ml SDD base for suspension, containing both colistin sulphate (20 mg/ml) and tobramycin sulphate (16 mg/ml).~Patients take the 5 ml amphotericin B, followed by the 5 ml SDD base for suspension, four times daily for one week, starting three days prior to the surgery. On the day of surgery, intake is limited to an early morning and a late evening dose.
Study: NCT06230861

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: Quercetin tablets 500mg 1 x per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control 1 x blinded placebo tablet per day
Study: NCT06196450

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vivomixx
Description: Vivomixx is a commercially available probiotic mixture consisting of eight probiotic lactic acid bacteria and Bifidobacteria including Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subspecies bulgaricus, Streptococcus salivarius subspecies thermophiles, Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline maltose
Description: Microcrystalline maltose as placebo
Study: NCT05208684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast stimulation
Description: Breast stimulation by the Elvie Pump to trigger prolactin release.
Study: NCT04984057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS is stopped when the pressure is equal between bPDA and aPDA.
Description: PS is given and stopped when the pressure is equal between bPDA and aPDA. the pressure is measured using ultrasound

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PS is given according to the 2019 European RDS management guideline
Description: PS is given according to the 2019 European RDS management guideline
Study: NCT06277258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Empowerment model
Description: Session I~* Knowledge about the disease, calories \& diet distribution, physical activities, symptoms of hypoglycemia, Blood Glucose target etc.~* Training on use of glucometer and record keeping Session II~* Evaluation and interpretation of sugar level based on the sugar chart.~* Tuning of diet and exercise if needed.~* Discussion about the challenges faced by the patient during maintenance of sugar level.~Session III \& ongoing~* Tuning of the diet based on calories, evaluation of the understanding~* Assessment of patient satisfaction~* Assessment of patients' knowledge and skill to designate her as Empowered~Assurance and counseling of patient and family will be rendered in each session.
Study: NCT05693480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balance sensor
Description: Participants will engage in the device test, clinical assessment tests, and related user experience surveys to uncover problems in the effectiveness, efficiency, and acceptance of the device prototype. The whole test will last six months, and the outcome will be assessed pre- and post-implementation for comparison and validation. The major testing criteria include the validity and reliability of the device, user experiences, and the accuracy of the device's fall prediction.
Study: NCT02131870

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L plantarum DSM 9843 or placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: L plantarum DSM 9843 or placebo
Study: NCT04810117

Intervention type: DIAGNOSTIC_TEST
Intervention: Serodiagnosis of IgG and IgM
Description: IgG and IgM antibodies will be detected in COVID-19 patients

Intervention type: DIAGNOSTIC_TEST
Intervention: Serodiagnosis of IgG and IgM
Description: IgG and IgM antibodies will be detected in COVID-19 patients
Study: NCT05053893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat;Sacubitril Valsartan Sodium Tablets;
Description: Select the appropriate dose according to the patient's situation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPO; ACEI / ARB
Description: Select the appropriate ACEI /ARB according to the subject's situation or follow its previous medication
Study: NCT05822518

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Neo-mune powder (otsuka pharmaceutical)
Description: * Preoperative: Neo-mune (otsuka pharmaceutical) powder 60 gm o.d. orally (contains glutamine, arginine and fish oil) for 3 days.~* Postoperative: Neo-mune (otsuka pharmaceutical) powder 60 gm o.d. orally (contains glutamine, arginine and fish oil) for 2 weeks starting when the intestinal sounds are audible.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipeptiven solution (Fresenius Kabi pharmaceutical)
Description: Dipeptiven (Fresenius Kabi pharmaceutical) solution 50 mg o.d IV ( contains L-ananyl-L-glutamine dipeptide) post operatively for 5 days starting from the operation day.
Study: NCT06663202

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fiber retention osseous resective surgery
Description: At the buccal and lingual sides, paramarginal or intrasulcular incisions will be made based on probing pocket depth values and the width of keratinised tissues.~Thinned palatal flap technique will be performed on the palatal side. Bone remodelling will be carefully made using manual or rotary instruments in order to reshape positive attached fibres/bony architecture utilising the FibReORS technique, great attention will be made to distinguish between inflammatory granulation tissue and connective tissue fibres attached to root cementum by means of periodontal probe. Flaps will be positioned at the level of the alveolar crest without tension.
Study: NCT04810117

Intervention type: DIAGNOSTIC_TEST
Intervention: Serodiagnosis of IgG and IgM
Description: IgG and IgM antibodies will be detected in COVID-19 patients

Intervention type: DIAGNOSTIC_TEST
Intervention: Serodiagnosis of IgG and IgM
Description: IgG and IgM antibodies will be detected in COVID-19 patients

Intervention type: DIAGNOSTIC_TEST
Intervention: Serodiagnosis of IgG and IgM
Description: IgG and IgM antibodies will be detected in COVID-19 patients

Intervention type: DIAGNOSTIC_TEST
Intervention: Serodiagnosis of IgG and IgM
Description: IgG and IgM antibodies will be detected in COVID-19 patients
Study: NCT06663202

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Papilla preservation flap
Description: Surgical access will be obtained using modified papilla preservation techniques and when interproximal space is narrow (less than 3mm in width) incision will be made using the simplified papilla preservation flap. Both flaps buccal and lingual/palatal will be elevated in any case to allow root surface cleaning and defects debridement under direct vision. Minimally invasive flap elevation preventing to damage inter proximal tissues with the preservation of the papilla. Defects debridement with mini-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Flaps will be positioned at the pre-surgical level without any tension. Monofilament non-resorbable 5-0 e-PTFE suturing material will be used. Suturing will be performed with external vertical mattress sutures to achieve primary intention closure.
Study: NCT06356194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1: Days 1-7 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. Days 8-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 BIK
Description: A co-administered dose of Bemnifosbuvir (BEM)/Ruzasvir (RZR) as separate formulations and Biktarvy (BIK)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2: Days 1-10 Biktarvy (BIK). Days 11-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered.
Description: A co-administered dose of Bemnifosbuvir (BEM)/Ruzasvir (RZR) as separate formulations and Biktarvy (BIK)
Study: NCT04567511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: bispecific monoclonal antibody binding to activated Factor IX and Factor X
Study: NCT06663202

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Widman flap procedure
Description: Surgical access will be obtained using the modified Widman flap technique. Intrasulcular incision will be done on both buccal and lingual/palatal sides without attempting to preserve the interdental tissues and interdental tissues will be removed. Both flaps buccal and lingual/palatal will be elevated at full thickness in any case to allow root surface cleaning and defects debridement under direct vision, a vertical releasing incision could be made when needed.~Defects debridement with mini-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Flaps will be positioned at the level of the alveolar crest without tension. Monofilament nonresorbable 5 - 0 e/PTFE suturing material will be used. Suturing will be performed with single interrupted sutures.
Study: NCT06661226

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accleration drills
Description: 14 participants will be in experimental group A, giving them acceleration drill protocol for six weeks. Measure all values before giving them protocol and after protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Change in Direction Drills
Description: 14 participants will be in experimental group B, giving them Change in direction drill protocol for six weeks. Measure all values before giving them protocol and after protocol.
Study: NCT04896632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INE 963
Description: Part A: Single ascending dose with 7 planned cohorts\> Part B: multiple dose with 2 planned cohort q24x3 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part A: single ascending dose with 7 planned cohorts. Part B: multiple dose with 2 planned q24x3 days.
Study: NCT06665451

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non coated dental implants
Description: Patients with fresh extraction sockets in the anterior maxilla will be treated by non coated immediate implant .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erythropoietin gel coated implants
Description: Patients with fresh extraction sockets in the anterior maxilla will be treated by immediate implant coated by erythropoietin gel.
Study: NCT06665633

Intervention type: DRUG
Group type: OTHER
Intervention: Oxygen 100 % Gas for Inhalation
Description: Oxygen 100% Gas for Inhalation in Hyperbaric Oxygen Therapy Chamber at 1.5 ATA

Intervention type: DEVICE
Group type: OTHER
Intervention: Hyperbaric Oxygen Therapy Chamber
Description: Hyperbaric Oxygen Therapy, 40 treatments, at 1.5 ATA and 100% Oxygen
Study: NCT06665867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video consultation
Description: Participants will have their follow-up consultation with the physician via video. The consultation takes place via the participant's/parent's own device.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face consultation
Description: The follow-up consultation with the physician will take place at the hospital.
Study: NCT06665126

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic + Probiotic Supplement
Description: This intervention includes a combination of prebiotics and probiotics designed to promote vaginal and digestive health. The supplement contains Biotin, Lactobacillus acidophilus (as LA-14®), Bifidobacterium lactis (HN019™), Lactobacillus rhamnosus (as HN001™), Lactobacillus crispatus (as CCFM1110™), Lactobacillus gasseri (as HLG13™), Lactobacillus reuteri (as HR7™), Bacillus subtilis (as DE111®), PreforPro®, White Rice Flour, Magnesium Stearate (Vegetable Source), Silicon Dioxide (Bamboo Source), and Cellulose (Vegetable Capsule). Participants take two capsules daily with food for 30 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Active Placebo Supplement
Description: The active placebo supplement contains similar probiotic strains without the prebiotic component. Ingredients include Biotin, Lactobacillus acidophilus, Bifidobacterium lactis, Lactobacillus rhamnosus, Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus reuteri, Bacillus subtilis, Inulin (from Chicory Root), White Rice Flour, Magnesium Stearate (Vegetable Source), Silicon Dioxide (Bamboo Source), and Cellulose (Vegetable Capsule). Participants take two capsules daily with food for 30 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Excipient Placebo Supplement
Description: The excipient placebo supplement contains no active ingredients related to prebiotics or probiotics. It includes White Rice Flour, Magnesium Stearate (Vegetable Source), and Cellulose (Vegetable Capsule). Participants take two capsules daily with food for 30 days.
Study: NCT06666452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COMFI - a COMbined Fatigue Intervention
Description: The COMFI intervention is a 24-week group-based outpatient fatigue intervention consisting of 1) Six group sessions based on CBA covering topics such as fatigue and related factors, PA, trying out PA, energy management, and enhancing peer support 2) a seventh group session intended as a booster session in week 24, 3) one optional individual session in week 6-9 of the intervention, and 4) a support line in week 13-23 of COMFI.
Study: NCT06665399

Intervention type: OTHER
Intervention: Observation
Description: In this study, the definition of observation is that participants cannot receive the following treatments currently considered to have a clear efficacy for NL-GLM/PDM, including surgical treatments (minimally invasive excision or open excision, incision and drainage), ultrasound-guided aspiration, oral corticosteroid therapy, antibiotic treatment, anti-tuberculosis therapy, or ductal lavage therapy. As symptomatic management for pain, the use of NSAIDs is permitted. Additionally, for patients with fistulas or skin lesions, routine wound care is also allowed. These two interventions are not considered as receiving treatment intervention in this study.